WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Lung Cancer efficacy endpoints v5m, Karnofsky with allowed values 0, 10, 20...100, -cough -shortness of breath -chest pain -fatigue -other specifying severity, Therapeutic Efficacy Endpoint is intersection of Therapeutic Intervention, Short axis for target lymph nodes measured in mm, Progression free survival (PFS) derived from Tumor Response, New lesion identified by Anatomical region, Informational or proposed for removal concepts identified by grey color boxes, Tumor Response assesses Lesion, Qualitative Assessment have response options -Complete Response (CR) -Non-CR/non-PD -Not evaluated -Not all evaluated -Non-PD -PD -Unequivocal PD -Any, Time to progression of cancer symptoms includes Name of the PRO instrument, Duration of response measured at Date of tumor progression, LD (axial plane) for target lesion measured in mm, Sum of longest diameters (SLD) has_component LD (axial plane) for target lesion, Anatomical region instantiated by -Lung -CNS (brain, leptomeninges) -Bone -Liver -Adrenal (L, R) -Mediastinum (anterior, middle, posterior) -Hilar (L, R) -Plural Fluid, Concepts are denoted by solid round-edged rectangle, New lesion identified by Organ specific lesion ID, LUNG CANCER EFFICACY ENDPOINTS include Time to progression of cancer symptoms, -Complete Response (CR) -Non-CR/non-PD -Not evaluated -Not all evaluated -Non-PD -PD -Unequivocal PD -Any summarized into OVERALL RESPONSE, - CR - PR differentiated into Unconfirmed Response, Repeated concepts/instances throughout the CMAP are denoted by dotted outline